Subgroup Analysis of the Phase 3 PhALLCON Study of Ponatinib in Ph+ ALL

EP: 1.The Evolving Treatment Landscape of Leukemia

EP: 2.Recent Data from ASH 2023 in Leukemia

EP: 3.Long-Term Results of the OPTIC Trial in CML

Now Viewing

EP: 4.Subgroup Analysis of the Phase 3 PhALLCON Study of Ponatinib in Ph+ ALL

EP: 5.Key Takeaways from Recent Updates in Leukemia

EP: 6.Challenges in Managing Adverse Events and Unmet Needs in Leukemia

EP: 7.The Evolving Lymphoma Treatment Landscape

EP: 8.Subcutaneous Mosunetuzumab in Follicular Lymphoma

EP: 9.Recent Data on Axi-Cel in Lymphoma

EP: 10.Primary Analysis of the SYMPATICO trial in Mantle Cell Lymphoma

EP: 11.CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma

EP: 12.Unmet Needs and Challenges in Lymphoma

This is a synopsis of a Peer Exchange series featuring James K. McCloskey, MD, and Lori A. Leslie, MD, of John Theurer Cancer Center, Hackensack University Medical Center.

Shifting to Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), James K. McCloskey, MD, Chief of the Leukemia Division at the John Theurer Cancer Center, discusses results from the phase 3 PhALLCON trial evaluating first-line ponatinib versus imatinib with chemotherapy. Unlike chronic phase chronic myeloid leukemia (CML), Ph+ ALL’s high relapse mortality necessitates maximally effective upfront therapy. Ponatinib’s potency against the emergent gatekeeper mutation T315I has made it an appealing option. However, randomized data was previously lacking.

PhALLCON fulfilled this need, combining ponatinib or imatinib with dose-adjusted chemotherapy backbones tailored to patients’ fitness. Updated results at the 2022 ASH Annual Meeting after a median 20 months of follow-up continue to demonstrate superior responses with ponatinib across all Ph+ ALL subsets. Specifically, major molecular response rates nearly quadrupled with ponatinib versus imatinib in patients over 60 years old, improving from 10% to 40%. This finding is clinically impactful since older patients have the greatest treatment challenges. Benefits were also seen for ponatinib in the P190 BCR-ABL variant and trended positive for the rarer P210 variant.

Encouragingly, safety profiles were comparable between ponatinib and imatinib with no new toxicities, complementing data from the OPTIC trial in CML. As Dr. McCloskey notes, these results continue building the evidence base for ponatinib’s approval in frontline Ph+ ALL. Its combination with blinatumomab is also yielding exciting chemo-free remission durability data. Overall, PhALLCON’s efficacy and safety updates further support ponatinib’s paradigm-changing potential to raise the treatment bar in Ph+ ALL, especially for older patients most in need of improved outcomes.

*Video synopsis is AI-generated and reviewed by OncLive editorial staff.